stem-cells-istock-577639302_posteriori

posteriori / iStockphoto.com

26 February 2018Americas

Kite teams up with Sangamo to treat cancer

Kite Pharma has entered into a collaboration with Sangamo Therapeutics that will see the companies develop next-generation engineered cell therapies to treat cancer.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Sangamo acquires biotech company for $84m

25 July 2018 California-based Sangamo Therapeutics has acquired biotech company TxCell for approximately €72 million.

Gilead follows Kite acquisition with $567m buy

12 December 2017 Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.

Kite accused of infringing Juno’s cancer immunotherapy

5 September 2017 Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

More on this story

Sangamo acquires biotech company for $84m

25 July 2018 California-based Sangamo Therapeutics has acquired biotech company TxCell for approximately €72 million.

Gilead follows Kite acquisition with $567m buy

12 December 2017 Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.

Kite accused of infringing Juno’s cancer immunotherapy

5 September 2017 Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

More on this story

Sangamo acquires biotech company for $84m

25 July 2018 California-based Sangamo Therapeutics has acquired biotech company TxCell for approximately €72 million.

Gilead follows Kite acquisition with $567m buy

12 December 2017 Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.

Kite accused of infringing Juno’s cancer immunotherapy

5 September 2017 Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB